Tianjing Biotech announces the progress of multiple registered clinical studies on the differentiated CD38 antibody fezetuzumab

Shanghai, China and Gaithersburg, USA October 13, 2021/PRNewswire/ - Tianjing Bio (the "Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization Biopharmaceutical companies are committed to target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provide new and effective treatment methods for the urgently needed cancer treatment fields around the world

The Phase 3 Registered Clinical Trial (NCT03952091) is a randomized, open, parallel-controlled, multi-center study on the progression-free survival (PFS) of the combination of fezetuzumab, lenalidomide and dexamethasone As the primary endpoint, the efficacy and safety of patients with relapsed or refractory multiple myeloma who have received at least first-line treatment in the past were evaluated compared with the dual regimen of lenalidomide and dexamethasone

Dr.

At present, Tianjing Biologics has completed the key clinical study of fizetuzumab for the third-line treatment of multiple myeloma.

In addition, the company plans to submit a clinical trial application for the combined treatment of multiple myeloma with Fizetuzumab and another self-developed product developed by Tianjing Biologics in the fourth quarter of 2021

About Fizetuzumab

Fizetuzumab (also known as TJ202/MOR202) is a human monoclonal antibody exclusively developed by German MorphoSys company using HuCAL technology

About Tianjing Biological

Tianjing Bio (NASDAQ: IMAB) is an innovative international biotechnology company focusing on the research and development, production and commercialization of differentiated and innovative biologic drugs in the field of tumor immunity

Source: Tianjing Biological